Offentliggørelse af det foreløbige resultat af Global Football Holdings, L.P.’s betingede, frivillige, offentlige tilbud vedrørende aktier i Brøndby IF
BRØNDBYERNES I.F. FODBOLD A/S
CVR-nr. 83 93 34 10
Brøndby, den 28. december 2022
SELSKABSMEDDELELSE NR. 21/2022
Offentliggørelse af det foreløbige resultat af Global Football Holdings, L.P.’s betingede, frivillige, offentlige tilbud vedrørende aktier i Brøndby IF
I forlængelse af selskabsmeddelelse nr. 16/2022 offentliggjort den 24. november 2022 kan selskabet oplyse, at Global Football Holdings L.P. (”GFH”) i dag offentliggør det foreløbige resultat af betingede, frivillige, offentlige tilbud vedrørende aktier i Brøndby IF (”Tilbuddet”) jf. § 21, stk. 3 i bekendtgørelse nr. 636 af 15. maj 2020 om overtagelsestilbud (”tilbudsbekendtgørelsen”). Tilbudsperioden udløb ifølge tilbudsdokumentet den 27. december 2022 kl. 17:00.
GFH har oplyst at det foreløbige resultat af Tilbuddet er som følger:
Den foreløbige og ikke-bindende sammentælling af acceptblanketter viser at GFH har modtaget gyldige accepter af Tilbuddet for 285.166.367 aktier svarende til 50.00000001% af Brøndby IF’s aktiekapital og samlede antal stemmerettigheder.
Som følge heraf kan GFH på en ikke-bindende basis oplyse at alle betingelser for Tilbuddet er blevet opfyldt og derfor vil GFH gennemføre Tilbuddet.
GFH har oplyst, at GFH senest den 30. december 2022 kl. 17:00 vil offentliggøre det endelige resultat af tilbuddet.
Selskabet henviser til vedhæftede meddelelse fra GFH, som hermed offentliggøres i overensstemmelse med § 20 i tilbudsbekendtgørelsen.
Bestyrelsen
Brøndby IF
Information
Yderligere information om denne meddelelse kan fås hos kommunikationschef Christian Schultz på telefon 31 41 41 85.
Vedhæftede filer
- Bilag til FBM nr. 21 - GFH - Offentliggørelse af foreløbigt resultat
- FBM nr. 21 2022 Brøndby IF - Offentliggørelse af det foreløbige resultat
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software8.12.2023 17:50:33 CET | Press release
PRESS RELEASE Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software Wolters Kluwer CCH Tagetik AI-based financial planning solution empowers finance professionals to make faster and better-informed decisions. New York – Dec. 8, 2023 – Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that it has been recognized as a Leader in the 2023 Gartner Magic Quadrant for Financial Planning Software. Earlier this month, Wolters Kluwer also received recognition as a Leader in the Gartner Magic Quadrant for Financial Close and Consolidation Software. CCH Tagetik Budgeting, Planning and Forecasting software is Wolters Kluwer’s AI-based, enterprise-wide planning solution, which helps global companies facilitate strategic, financial, and operational planning, including supply chain, workforce, and capital expenses. The solution, which supports customers across vertical industries, is particula
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment8.12.2023 17:50:00 CET | Press release
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programme Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment. A statistically significant and clinically meaningful improvement in overall survival (OS), a secondary endpoint, was observed with adjuvant (post-surgery) Kadcyla® (trastuzumab emtansine) compared to Herceptin® (trastuzumab): at the 7-year landmark OS rates were 89.07% and 84.37
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation8.12.2023 17:45:00 CET | Press release
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5 These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authorities Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.1 The inavolisib combination reduced the risk of disease worsening or death (progression-free survival; PFS) by 57% compared to palbociclib and fulvestrant alone (15.0 months vs 7.3 months;
Innofactor Plc: Share Repurchase 8.12.20238.12.2023 17:30:00 CET | Press release
Innofactor Plc Announcement 8.12.2023Innofactor Plc: Share Repurchase 8.12.2023In the Helsinki Stock ExchangeTrade date 8.12.2023Bourse trade BuyShare IFA1VAmount 4,400SharesAverage price/ share 1.1700EURTotal cost 5,148.00EURInnofactor Plc now holds a total of 580 029 sharesincluding the shares repurchased on 8.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 2029sami.ensio@innofactor.comwww.innofactor.com Attachment Innofactor_8.12_trades
Azerion publishes bond prospectus and applies for admission to trading of its bonds on Nasdaq Stockholm8.12.2023 17:26:44 CET | Press release
Amsterdam, 8 December 2023 – Azerion Group N.V. (the “Company”) has, on 14 September 2023, following a bookbuilding process, successfully placed EUR 165 million of senior secured floating rate bonds under a framework of EUR 300 million to qualified institutional investors internationally (the "Bonds"). The Dutch Authority for the Financial Markets (Autoriteit Financiële Markten (the “AFM”)) has on 8 December 2023 approved the prospectus in relation to the admission to trading of the Bonds (the "Prospectus"). The approval of the Prospectus has been notified to the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The Prospectus will be available on the AFM’s website (https://www.afm.nl/en/sector/registers/meldingenregisters/goedgekeurde-prospectussen) and, together with a Swedish translation of the summary of the Prospectus, on the Company’s website (https://www.azerion.com/reports/). The Company will apply for listing of the Bonds on the Corporate Bond List of Nasdaq St